• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer

firstwordpharmaAugust 23, 2021

Tag: Vividion , VVID , IPO

Vividion Therapeutics withdrew its plans for an initial public offering after announcing earlier this month that it would be acquired by Bayer for up to $2 billion, Renaissance Capital reported.

The company was founded in 2013 and had disclosed plans in June to raise $100 million and list on the Nasdaq under the symbol VVID.


Previous:XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Next:Cuba grants emergency approval to second homegrown vaccine

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

α-Lipoic Acid

α-Lipoic Acid
R-（+）-Alpha Lipoic Acid

R-（+）-Alpha Lipoic Acid
Ipomoea Dragon Extract

Ipomoea Dragon Extract
Siponimod

Siponimod
Microfluidic liposome mixer

Microfluidic liposome mixer
Tripossium Glycyrrhiznate

Tripossium Glycyrrhiznate
Alpha Lipoic Acid

Alpha Lipoic Acid
dipotassium glycyrrhizinate

dipotassium glycyrrhizinate
Ethylenediaminetetraacetic acid dipotassium salt dihydrate

Ethylenediaminetetraacetic acid dipotassium salt dihydrate
Siponimod

Siponimod

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service